NLS‑RARα modulates acute promyelocytic leukemia NB4 cell proliferation and differentiation via the PI3K/AKT pathway

Song,Hao; Li,Liu; Zhong,Liang; Yang,Rong; Jiang,Kailing; Yang,Xiaoqun; Liu,Beizhong

doi:10.3892/mmr.2016.5932

NLS‑RARα modulates acute promyelocytic leukemia NB4 cell proliferation and differentiation via the PI3K/AKT pathway

Authors:
- Hao Song
- Liu Li
- Liang Zhong
- Rong Yang
- Kailing Jiang
- Xiaoqun Yang
- Beizhong Liu
View Affiliations

Affiliations: Central Laboratory of Yong‑Chuan Hospital, Chongqing Medical University, Chongqing 402160, P.R. China, Department of Laboratory Medicine, The Key Laboratory of Diagnostics Medicine Designated by The Ministry of Education, Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: November 8, 2016 https://doi.org/10.3892/mmr.2016.5932
Pages: 5495-5500
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In patients with acute promyelocytic leukemia (APL), ~98% express the promyelocytic leukemia (PML)‑retinoic acid receptor α (RARα) fusion protein. Previous studies have shown that, in primary leukemia cells of patients with APL, the cleavage of PML‑RARα by neutrophil elastase is important for its ability to initiate APL. This cleavage separates the nuclear localization signal (NLS) from PML, leading to the formation of a novel protein, NLS‑RARα, although its underlying mechanism in APL remains to be fully elucidated. In the present study, the role of NLS‑RARα on the proliferation and differentiation of APL NB4 cells was investigated. Lentiviral vectors were constructed and transfected NLS‑RARα in NB4 cells, puromycin was used to select the stable transfected cell lines. Cell Counting Kit‑8 and flow cytometry analysis revealed that the efficient overexpression of NLS‑RARα significantly promoted NB4 cell proliferation and inhibited all‑trans retinoic acid‑induced cell differentiation. Furthermore, the NLS‑RARα protein promoted a significant increase in AKT and glycogen synthase kinase 3β (GSK‑3β) phosphorylation. The protein levels of phosphorylated (p) AKT and pGSK‑3β were decreased following pretreatment with the phosphatidylinositol 3‑kinase (PI3K) inhibitor, LY294002. These findings suggested that NLS‑RARα was an important molecule associated with the occurrence of APL via the PI3K‑AKT signaling pathway, and indicated that the NLS‑RARα protein may be a novel target for the treatment of APL.

View Figures

View References

1	Warrell RP Jr, de Thé H, Wang ZY and Degos L: Acute promyelocytic leukemia. N Engl J Med. 329:177–189. 1993. View Article : Google Scholar : PubMed/NCBI
2	Lo-Coco F and Cicconi L: History of acute promyelocytic leukemia: A tale of endless revolution. Mediterr J Hematol Infect Dis. 3:e20110672011. View Article : Google Scholar : PubMed/NCBI
3	Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, et al: The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 74:423–431. 1993. View Article : Google Scholar : PubMed/NCBI
4	Laurenzana A, Pettersson F and Miller WH Jr: Role of PML-RARα in the pathogenesis of APL. Drug Discov Today Dis Mech. 3:499–505. 2006. View Article : Google Scholar
5	Lane AA and Ley TJ: Neutrophil elastase cleaves PML-RARalpha and is important for the development of acute promyelocytic leukemia in mice. Cell. 115:305–318. 2003. View Article : Google Scholar : PubMed/NCBI
6	Lane AA and Ley TJ: Neutrophil elastase is important for PML-retinoic acid receptor alpha activities in early myeloid cells. Mol Cell Biol. 25:23–33. 2005. View Article : Google Scholar : PubMed/NCBI
7	di Masi A, Leboffe L, De Marinis E, Pagano F, Cicconi L, Rochette-Egly C, Lo-Coco F, Ascenzi P and Nervi C: Retinoic acid receptors: From molecular mechanisms to cancer therapy. Mol Aspects Med. 41:1–115. 2015. View Article : Google Scholar : PubMed/NCBI
8	Wang ZY and Chen Z: Acute promyelocytic leukemia: From highly fatal to highly curable. Blood. 111:2505–2515. 2008. View Article : Google Scholar : PubMed/NCBI
9	Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhao L, Gu LJ and Wang ZY: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 72:567–572. 1988.PubMed/NCBI
10	Breccia M, Cicconi L and Lo-Coco F: ATRA+ ATO: Has a new standard of care been established in low-risk acute promyelocytic leukaemia? Curr Opin Hematol. 21:95–101. 2014. View Article : Google Scholar : PubMed/NCBI
11	Iland HJ and Seymour JF: Role of arsenic trioxide in acute promyelocytic leukemia. Curr Treat Options Oncol. 14:170–184. 2013. View Article : Google Scholar : PubMed/NCBI
12	Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, Altman JK, Douer D, Rowe JM and Tallman MS: Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 118:1248–1254. 2011. View Article : Google Scholar : PubMed/NCBI
13	De Braekeleer E, Douet-Guilbert N and De Braekeleer M: RARA fusion genes in acute promyelocytic leukemia: A review. Expert Rev Hematol. 7:347–357. 2014. View Article : Google Scholar : PubMed/NCBI
14	Soprano DR, Qin P and Soprano KJ: Retinoic acid receptors and cancers. Annu Rev Nutr. 24:201–221. 2004. View Article : Google Scholar : PubMed/NCBI
15	Wang H, Zhong L, Jiang KL, Zhu XY, Ma PP, Yang XQ and Liu BZ: Location verification of NLS-RARα protein in infected NB4 cell line with adenovirus Ad-NE. Chin J Cell Biol. 36:331–337. 2014.(In Chinese).
16	Marshall KS, Cohen MJ, Fonseca GJ, Todorovic B, King CR, Yousef AF, Zhang Z and Mymryk JS: Identification and characterization of multiple conserved nuclear localization signals within adenovirus E1A. Virology. 454-455:206–214. 2014. View Article : Google Scholar : PubMed/NCBI
17	Sun Z, Wu T, Zhao F, Lau A, Birch CM and Zhang DD: KPNA6 (Importin {alpha}7)-mediated nuclear import of Keap1 represses the Nrf2-dependent antioxidant response. Mol Cell Biol. 31:1800–1811. 2011. View Article : Google Scholar : PubMed/NCBI
18	Rizzatti EG, Garcia AB, Portieres FL, Silva DE, Martins SL and Falcão RP: Expression of CD117 and CD11b in bone marrow can differentiate acute promyelocytic leukemia from recovering benign myeloid proliferation. Am J Clin Pathol. 118:31–37. 2002. View Article : Google Scholar : PubMed/NCBI
19	Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
20	Cumberbatch M, Tang X, Beran G, Eckersley S, Wang X, Ellston RP, Dearden S, Cosulich S, Smith PD, Behrens C, et al: Identification of a subset of human non-small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in squamous cell carcinoma. Clin Cancer Res. 20:595–603. 2014. View Article : Google Scholar : PubMed/NCBI
21	Xie X, Tang B, Zhou J, Gao Q and Zhang P: Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Oncol Rep. 30:773–782. 2013.PubMed/NCBI
22	Henriksson M and Lüscher B: Proteins of the Myc network: Essential regulators of cell growth and differentiation. Adv Cancer Res. 68:109–182. 1996. View Article : Google Scholar : PubMed/NCBI
23	Wray J, Kalkan T, Gomez-Lopez S, Eckardt D, Cook A, Kemler R and Smith A: Inhibition of glycogen synthase kinase-3 alleviates Tcf3 repression of the pluripotency network and increases embryonic stem cell resistance to differentiation. Nat Cell Biol. 13:838–845. 2011. View Article : Google Scholar : PubMed/NCBI
24	Ougolkov AV and Billadeau DD: Targeting GSK-3: A promising approach for cancer therapy? Future Oncol. 2:91–100. 2006. View Article : Google Scholar : PubMed/NCBI
25	Diehl JA, Cheng M, Roussel MF and Sherr CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Gene Dev. 12:3499–3511. 1998. View Article : Google Scholar : PubMed/NCBI
26	Qiao J, Paul P, Lee S, Qiao L, Josifi E, Tiao JR and Chung DH: PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation. Biochem Biophs Res Commun. 424:421–426. 2012. View Article : Google Scholar
27	Kim JM, Yoon M, Kim J and Kim SS, Kang I, Ha J and Kim SS: Phosphatidylinositol 3-kinase regulates differentiation of H9c2 cardiomyoblasts mainly through the protein kinase B/Akt-independent pathway. Arch Biochem Biophys. 367:67–73. 1999. View Article : Google Scholar : PubMed/NCBI
28	Ozpolat B, Akar U, Steiner M, Zorrilla-Calancha I, Tirado-Gomez M, Colburn N, Danilenko M, Kornblau S and Berestein GL: Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res. 5:95–108. 2007. View Article : Google Scholar : PubMed/NCBI
29	Srinivas H, Xia D, Moore NL, Uray IP, Kim H, Ma L, Weigel NL, Brown PH and Kurie JM: Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. Biochem J. 395:653–662. 2006. View Article : Google Scholar : PubMed/NCBI
30	Jiang K, Yang X, Ma P, Wang H, Zhu X, Liu B and Zhong L: NLS-RARα: A novel transcriptional factor. Oncol Lett. (In press).